Jun 2026 (Q2 FY26) — Aug 12, 2026
Atea Pharmaceuticals Q2 FY26 — Positive Phase 3 C-Beyond Results and Pipeline Advancement
Read the full callAtea Pharmaceuticals (AVIR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Atea Pharmaceuticals earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -32.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.39 +1.62% · +$0.07
Performance +43.5% 1Y
1Y: $3.06 on 17 Oct 2025 → $4.39. High $6.15 (9 Mar 2026), low $2.96 (14 Nov 2025).
- Previous close
- $4.32
- 52-week range
- $2.96 – $6.15
- One year
- +36.34%
Overview
- Symbol
- AVIR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Atea Pharmaceuticals earnings calls (AVIR)
Financials
What the filings say
Net profit, year on year: +11% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -37 | -39 | -39 | -41 | -46 | -55 | -48 | -35 |
| Profit before tax | -31 | -33 | -34 | -37 | -42 | -52 | -45 | -33 |
| Tax rate | −0.7% | −0.7% | −0.6% | −0.6% | −0.5% | 13.1% | −0.1% | −0.1% |
| Net profit | -31 | -34 | -34 | -37 | -42 | -45 | -45 | -33 |
| EPS ($ per share) | -0.37 | — | -0.40 | -0.44 | -0.53 | — | -0.57 | -0.41 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -54 | -65 | 56 | -60 | -196 | -364 | -523 |
| Total liabilities | — | 3 | 316 | 63 | 26 | 40 | 26 | 40 |
| Fixed assets | — | 0 | 0 | 0 | 2 | 1 | 1 | 0 |
| Total assets | — | 22 | 864 | 773 | 667 | 595 | 465 | 315 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8 | -13 | 297 | -87 | -121 | -85 | -135 | -132 |
| Cash from investing | -0 | -0 | -0 | -0 | -455 | 40 | 56 | 189 |
| Cash from financing | 27 | — | 532 | 1 | 0 | 0 | 0 | -26 |
| Net cash flow | 20 | -13 | 828 | -86 | -576 | -45 | -79 | 31 |
| Capital expenditure | -0 | -0 | -0 | -0 | -2 | — | — | — |
| Free cash flow | -8 | -13 | 297 | -87 | -123 | — | — | — |
Insider filings
21 filings between Jan 31, 2026 and Jun 18, 2026.
Open market
decisions to buy or sellPurchases
$25.4K
1 purchase by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 14
- Option exercise — converted options into shares
- 6
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Murphy Polly A. | $25.4K | — | May 18, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 18, 2026 | Duncan Barbara Gayle Director | Option exercise | 29,600 | $0 |
| Jun 18, 2026 | Polsky Bruce Director | Option exercise | 29,600 | $0 |
| Jun 18, 2026 | Adams Jerome M. Director | Option exercise | 29,600 | $0 |
| Jun 18, 2026 | BERGER FRANKLIN M Director | Option exercise | 29,600 | $0 |
| Jun 18, 2026 | Lucidi Bruno Director | Option exercise | 29,600 | $0 |
| Jun 18, 2026 | Murphy Polly A. Director | Option exercise | 29,600 | $0 |
| May 18, 2026 | Murphy Polly A. Director | Purchase | 6,100 | $25.4K |
| Mar 11, 2026 | Corcoran Andrea See Remarks | Option exercise | 60,000 | $74.4K |
| Feb 3, 2026 | Sommadossi Jean-Pierre President, CEO, and Chairman | Option exercise | 300,000 | $372.0K |
| Jan 31, 2026 | Vavricka John Chief Commercial Officer | Option exercise | 42,083 | — |
| Jan 31, 2026 | Vavricka John Chief Commercial Officer | Tax withheld | 11,570 | $49.1K |
| Jan 31, 2026 | Horga Maria Arantxa Chief Medical Officer | Tax withheld | 16,073 | $68.1K |
| Jan 31, 2026 | Horga Maria Arantxa Chief Medical Officer | Option exercise | 51,283 | — |
| Jan 31, 2026 | Foster Wayne EVP, Chief Accounting Officer | Option exercise | 41,333 | — |
| Jan 31, 2026 | Foster Wayne EVP, Chief Accounting Officer | Tax withheld | 12,132 | $51.4K |
| Jan 31, 2026 | Sommadossi Jean-Pierre President, CEO, and Chairman | Option exercise | 272,983 | — |
| Jan 31, 2026 | Sommadossi Jean-Pierre President, CEO, and Chairman | Tax withheld | 106,093 | $449.8K |
| Jan 31, 2026 | Corcoran Andrea See Remarks | Option exercise | 54,866 | — |
| Jan 31, 2026 | Corcoran Andrea See Remarks | Tax withheld | 16,104 | $68.3K |
| Jan 31, 2026 | Hammond Janet MJ Chief Development Officer | Option exercise | 58,050 | — |
| Jan 31, 2026 | Hammond Janet MJ Chief Development Officer | Tax withheld | 14,136 | $59.9K |
| Jun 20, 2025 | Adams Jerome M. Director | Option exercise | 29,600 | $0 |
| Jun 20, 2025 | Lucidi Bruno Director | Option exercise | 29,600 | $0 |
| Jun 20, 2025 | Polsky Bruce Director | Option exercise | 29,600 | $0 |
| Jun 20, 2025 | BERGER FRANKLIN M Director | Option exercise | 29,600 | $0 |
| Jun 20, 2025 | Murphy Polly A. Director | Option exercise | 29,600 | $0 |
| Jun 20, 2025 | Duncan Barbara Gayle Director | Option exercise | 29,600 | $0 |
| May 18, 2025 | Murphy Polly A. Director | Purchase | 6,100 | $25.4K |
| Jan 31, 2025 | Foster Wayne EVP, Chief Accounting Officer | Option exercise | 33,333 | — |
| Jan 31, 2025 | Foster Wayne EVP, Chief Accounting Officer | Award | 8,000 | — |
| Jan 31, 2025 | Foster Wayne EVP, Chief Accounting Officer | Tax withheld | 12,062 | $36.9K |
| Jan 31, 2025 | Sommadossi Jean-Pierre President, CEO, and Chairman | Option exercise | 173,467 | — |
| Jan 31, 2025 | Sommadossi Jean-Pierre President, CEO, and Chairman | Award | 99,517 | — |
| Jan 31, 2025 | Sommadossi Jean-Pierre President, CEO, and Chairman | Tax withheld | 88,601 | $271.1K |
| Jan 31, 2025 | Corcoran Andrea See Remarks | Option exercise | 44,367 | — |
| Jan 31, 2025 | Corcoran Andrea See Remarks | Award | 10,500 | — |
| Jan 31, 2025 | Corcoran Andrea See Remarks | Tax withheld | 16,102 | $49.3K |
| Jan 31, 2025 | Horga Maria Arantxa Chief Medical Officer | Option exercise | 41,533 | — |
| Jan 31, 2025 | Horga Maria Arantxa Chief Medical Officer | Award | 9,750 | — |
| Jan 31, 2025 | Vavricka John Chief Commercial Officer | Option exercise | 33,333 | — |
| Jan 31, 2025 | Vavricka John Chief Commercial Officer | Award | 8,750 | — |
| Jan 31, 2025 | Vavricka John Chief Commercial Officer | Tax withheld | 11,517 | $35.2K |
| Jan 31, 2025 | Hammond Janet MJ Chief Development Officer | Option exercise | 46,800 | — |
| Jan 31, 2025 | Hammond Janet MJ Chief Development Officer | Award | 11,250 | — |
| Jan 31, 2025 | Hammond Janet MJ Chief Development Officer | Tax withheld | 14,134 | $43.3K |
| Jan 31, 2025 | Horga Maria Arantxa Chief Medical Officer | Tax withheld | 16,071 | $49.2K |
| Jan 16, 2025 | BERGER FRANKLIN M Director | Purchase | 10,000 | $33.6K |
| Jan 15, 2025 | BERGER FRANKLIN M Director | Purchase | 15,000 | $47.9K |
| Dec 10, 2024 | BERGER FRANKLIN M Director | Sale | 359,606 | $1.02M |
| Sep 19, 2024 | Sommadossi Jean-Pierre President, CEO, and Chairman | Sale 10b5-1 plan | 1,841 | $7.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Atea Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Atea Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading